Amiri-Dashatan Nasrin, Koushki Mehdi, Naghi-Zadeh Mohsen, Razzaghi Mohammad Reza, Mohaghegh Shalmani Hamid
Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Gastroenterol Hepatol Bed Bench. 2021 Fall;14(Suppl1):S1-S9.
This meta-analysis was designed to reassess the prognostic and clinicopathologic values of the microRNA-125 family in GC patients.
The miR-125 family (including miR-125a, miR-125b) has been reported as being pivotal prognostic biomarkers of gastric cancer (GC). However, there is controversy about the role of the miR-125 family in predicting the progression of GC.
The miR-125 family (including miR-125a, miR-125b) has been reported as being pivotal prognostic biomarkers of gastric cancer (GC). However, there is controversy about the role of the miR-125 family in predicting the progression of GC.
The electronic databases of PubMed, ISI Web of Science, Scopus, and Cochrane Library were systematically searched for relevant studies. Overall survival (OS) rate as the primary outcome from each study was extracted. The overall hazard ratio (HR or survival rate in patients with GC) and odds ratio (OR) with 95% confidence interval (CI) was calculated to evaluate the association between miR-125 family expression and prognosis and susceptibility to gastric cancer. The quality of evidence was evaluated using the Newcastle-Ottava Scale (NOS). The extracted data was combined based on the random-effects model.
The low expression of miR-125 family predicts poor OS in GC patients. Thus, the miR-125 family may be helpful as a potential biomarker for the prognosis of gastric cancer.
本荟萃分析旨在重新评估微小RNA - 125家族在胃癌患者中的预后及临床病理价值。
据报道，miR - 125家族（包括miR - 125a、miR - 125b）是胃癌（GC）的关键预后生物标志物。然而，miR - 125家族在预测GC进展中的作用存在争议。
对PubMed、ISI Web of Science、Scopus和Cochrane图书馆的电子数据库进行系统检索以查找相关研究。提取每项研究中作为主要结局的总生存率（OS）。计算总体风险比（HR，即GC患者的生存率）和比值比（OR）以及95%置信区间（CI），以评估miR - 125家族表达与胃癌预后及易感性之间的关联。使用纽卡斯尔 - 渥太华量表（NOS）评估证据质量。基于随机效应模型合并提取的数据。
miR - 125家族低表达预示GC患者的OS较差。因此，miR - 125家族可能作为胃癌预后的潜在生物标志物具有一定帮助。
